Lay summary
People with kidney failure experience severe symptoms that have insufficient treatment options. Symptoms reduce quality of life and life participation for patients and their whānau. We will explore perspectives of prescribed cannabinoids of patients and stakeholders through (1) a systematic review with meta-analysis of the effects of treatment and (2) an in-depth interview study with people with kidney failure, whānau and clinicians. We will then design a feasibility trial.